Deferoxamine (Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine)

Name: Deferoxamine
Brand: MedChemExpress
SKU: HY-B1625
Rating: 5.0 (232 reviews)

Cat. No.: HY-B1625 Purity: 99.20%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.

For research use only. We do not sell to patients.

Deferoxamine Chemical Structure

CAS No. : 70-51-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 259	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 259	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 210	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 340	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 232 publication(s) in Google Scholar

Other Forms of Deferoxamine:

Deferoxamine mesylate In-stock
Deferoxamine (Standard) Get quote

218 Publications Citing Use of MCE Deferoxamine

RT-PCR

Proliferation Assay

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Mar 4;8(9):eabm1896. [Abstract]; PAI1 mRNA expression in iHUVEC treated with increasing doses of either CoCl2, Deferoxamine (DFO), 1, 4-DPCA or DMOG.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043. [Abstract]; The specific inhibitor of ferroptosis Fer-1 (100 μM) and Lip-1 (5 μM), and the iron chelator Deferoxamine (DFOM;100 μM) restored the cellular activity of RAW264.7 macrophages after treatment for 24 h.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043. [Abstract]; Deferoxamine (DFOM; 100 μM; 24 h) attenuated the abnormal increase of ROS and LPO in macrophages elicited by CdTe QDs.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36. [Abstract]; H1299 cells are treated with Curcumenol with or without Deferoxamine (DFO; 20 μM) for 24 h, and the cell viability is analyzed.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36. [Abstract]; The expression of ferroptosis-related proteins in lung cancer cells is detected after Curcumenol treatment with or without Deferoxamine (DFO; 20 μM) by western blotting.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Mar 8;8(10):2004680. [Abstract]; Deferoxamine (DFO; 0.5 μM; for 48 h) could rescue iron overload‐induced cell death in both iHep‐Orgs and iHep.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jun;11(6):1513-1525. [Abstract]; Deferoxamine (DFO; 10 μM; 72 h) can markedly reverse the cell growth prevented by a2 in MGC-803 and MKN-45 cells.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206. [Abstract]; Propidium iodide staining confirmed that DFO inhibited metformin-induced cell death in T47D cells Deferoxamine (20 μM; 48 h).

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51. [Abstract]; Representative results of wound healing after the treatment with the combination of ferroptosis inhibitor DFO and erianin. The expression of EMT markers E-Cadherin and N-Cadherin are examined by western blotting.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119. [Abstract]; The cell death induced by the treatment with β-elemene and cetuximab in KRAS mutant CRC cells is almost completely blocked by treatment with ferroptosis rescue agents Deferoxamine (DFO; 20 nM; 24 h), Liproxstatin-1 (Lip-1) or Ferrostatin-1 (Fer-1).

: Deferoxamine purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173. [Abstract]; The expression of iron metabolism related protein is assessed by western blot. Protein levels of FPN1 and hepcidin1 in the liver. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloaded

: Deferoxamine purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173. [Abstract]; The expression of iron metabolism related protein was assessed by western blot. Protein levels of TfR1, FTH1 and FPN1 in the tibia. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloade

: Deferoxamine purchased from MedChemExpress. Usage Cited in: Cell Res. 2018 Dec;28(12):1171-1185. [Abstract]; The FTL- or FTH1-knockdown A375 cells are pretreated with or without DFO (50 μM) for 2 h before CCCP stimulation. The pyroptotic morphology and LDH release are indicated.

: Deferoxamine purchased from MedChemExpress. Usage Cited in: ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6180-6189. [Abstract]; Quantitative analyses confirm the steady increase of blood vessels over the course of implantation of DFO-loading Gp gel.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Isoforms

HIF-1α HIF

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	3.5 μM Compound: DFO	Antiproliferative activity against human A2780 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells incubated for 72 hrs by MTT assay	[PMID: 36105345]
A549	IC₅₀	7.5 μM Compound: DFO	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay Antiproliferative activity at human A549 cells after 72 hrs by MTT assay	[PMID: 22861499]
DMS-53	IC₅₀	10 μM Compound: DFO	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay	[PMID: 22861499]
HCT-116	IC₅₀	> 200 μM Compound: I, DFO	Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay	[PMID: 24900837]
HCT-116	IC₅₀	> 200 μM Compound: I, DFO	Dark cytotoxicity against p53-deficient human HCT116 cells after 96 hrs by MTT assay Dark cytotoxicity against p53-deficient human HCT116 cells after 96 hrs by MTT assay	[PMID: 24900837]
HeLa	IC₅₀	> 50 μM Compound: DFO, desferoxamine	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	[PMID: 18345610]
HepaRG	IC₅₀	50 μM Compound: DFO	Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay	[PMID: 20036563]
HepaRG	IC₅₀	70 μM Compound: DFO	Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay in presence of iron(3) Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay in presence of iron(3)	[PMID: 20036563]
HepG2	IC₅₀	> 100 μM Compound: DFO	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 29233652]
HL-60	GI₅₀	18.4 μM Compound: DFO	Cytotoxicity against human HL60 cells by alamar blue assay Cytotoxicity against human HL60 cells by alamar blue assay	[PMID: 23266185]
HT-29	IC₅₀	36.1 μM Compound: DFO, desferoxamine	Cytotoxicity against human HT29 cells after 72 hrs by MTS assay Cytotoxicity against human HT29 cells after 72 hrs by MTS assay	[PMID: 18345610]
MDA-MB-231	IC₅₀	6.1 μM Compound: DFO	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 36105345]
MDCK	IC₅₀	9.49 μM Compound: 1, DFOB	Toxicity in MDCK cells by MTT method Toxicity in MDCK cells by MTT method	[PMID: 20041672]
MRC5	IC₅₀	> 10 μM Compound: DFO	Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay	[PMID: 22861499]
MRC5	IC₅₀	9 μM Compound: DFO	Antiproliferative activity against human MRC5 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MRC5 cells incubated for 72 hrs by MTT assay	[PMID: 36105345]
NIH3T3	IC₅₀	4.9 μM Compound: DFO	Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay	[PMID: 31531196]
NIH3T3	IC₅₀	9 μM Compound: DFO	Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay	[PMID: 31531196]
SK-N-MC	IC₅₀	10 μM Compound: DFO	Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 22861499]
SK-N-MC	IC₅₀	12.5 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 22858101]
SK-N-MC	IC₅₀	14.22 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells by MTT assay Antiproliferative activity against human SK-N-MC cells by MTT assay	[PMID: 17963372]
SK-N-MC	IC₅₀	16.04 μM Compound: 1, DFOB	Toxicity in human SK-N-MC cells by MTT method Toxicity in human SK-N-MC cells by MTT method	[PMID: 20041672]
SK-N-MC	IC₅₀	16.81 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 28841514]
SK-N-MC	IC₅₀	17.07 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 22172311]
SK-N-MC	IC₅₀	17.07 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 21055950]
SK-N-MC	IC₅₀	21.63 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay	[PMID: 23312948]
SK-N-MC	IC₅₀	22.7 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay	[PMID: 21846118]
SK-N-MC	IC₅₀	22.7 μM Compound: DFO	Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23276209]
SK-N-MC	IC₅₀	4.51 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 17602603]
SK-N-MC	IC₅₀	5 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 19601577]
SK-N-MC	IC₅₀	7.35 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 19216562]
SK-N-MC	IC₅₀	8.58 μM Compound: DFO	Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay	[PMID: 17064069]
SK-N-MC	IC₅₀	9.89 μM Compound: DFO	Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 20303768]
U2OS	EC₅₀	17.8 μM Compound: DFO	Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay	[PMID: 22172704]
U373-MAGI	CC₅₀	> 400 μM Compound: Deferoxamine	Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay	[PMID: 24120088]
U373-MAGI	EC₅₀	384 μM Compound: Deferoxamine	Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry	[PMID: 24120088]

In Vitro

Deferoxamine (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells^[1].
Deferoxamine (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels^[2].
Deferoxamine (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs^[3].
Deferoxamine (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs^[3].
Deferoxamine (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs^[3].
Deferoxamine (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MEFs cells
Concentration:	1 mM
Incubation Time:	16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
Result:	Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions. Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

Western Blot Analysis^[2]

Cell Line:	HepG2 cells
Concentration:	100 µM
Incubation Time:	24 h
Result:	Showed a twofold increase of InsR mRNA levels in cells. Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

Cell Proliferation Assay^[3]

Cell Line:	TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
Concentration:	5, 10, 25, 50, 100 µM
Incubation Time:	7 days (TAMSCs); 9 days (BMMSCs).
Result:	Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 µM dose.

Apoptosis Analysis^[3]

Cell Line:	TAMSCs, BMMSCs
Concentration:	5, 10, 25, 50, 100 µM
Incubation Time:	7 days
Result:	Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

Western Blot Analysis^[3]

Cell Line:	TAMSCs, BMMSCs
Concentration:	10 µM
Incubation Time:	3 days
Result:	Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

Cell Autophagy Assay^[4]

Cell Line:	SH-SY5Y cells
Concentration:	100 µM
Incubation Time:	24 h
Result:	Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection. Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.

In Vivo

Deferoxamine (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice^[1].
Deferoxamine (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)^[1].
Dosage:	560.68 mg/per (10 uL of 1 mM)
Administration:	Drip-on; once daily for 21 days.
Result:	Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.

Animal Model:	Male Sprague-Dawley rats (180-200 g)^[2].
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; daily for 2 weeks.
Result:	Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.

Clinical Trial

Molecular Weight

560.68

Formula

C₂₅H₄₈N₆O₈

CAS No.

70-51-9

Appearance

Solid

Color

White to off-white

SMILES

O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (17.84 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7835 mL	8.9177 mL	17.8355 mL
5 mM	0.3567 mL	1.7835 mL	3.5671 mL
10 mM	0.1784 mL	0.8918 mL	1.7835 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (2.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.76%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (240 KB) HNMR (284 KB) LCMS (89 KB)

Handling Instructions (2659 KB)

References

[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e. [Content Brief]

[2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47. [Content Brief]

[3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. [Content Brief]

[4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205. [Content Brief]

[5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7835 mL	8.9177 mL	17.8355 mL	44.5887 mL
	5 mM	0.3567 mL	1.7835 mL	3.5671 mL	8.9177 mL
	10 mM	0.1784 mL	0.8918 mL	1.7835 mL	4.4589 mL
	15 mM	0.1189 mL	0.5945 mL	1.1890 mL	2.9726 mL

Deferoxamine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Deferoxamine (Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine)

Customer Review

Other Forms of Deferoxamine:

218 Publications Citing Use of MCE Deferoxamine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Akt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Deferoxamine Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Deferoxamine (Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine)

Customer Review

Other Forms of Deferoxamine:

Deferoxamine Related Antibodies

218 Publications Citing Use of MCE Deferoxamine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Akt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Deferoxamine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Deferoxamine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report